Navigation Links
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
Date:11/4/2014

SAN DIEGO, Nov. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer.

"We are very pleased to welcome Darin Lippoldt to the Neurocrine leadership team as our Chief Legal Officer," said Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences. "Darin's breadth of experience in both developmental and commercial biotechnology companies will be of critical importance as Neurocrine evolves into a fully-integrated pharmaceutical company."

Prior to joining Neurocrine, Mr. Lippoldt served as Executive Vice President and General Counsel of Volcano Corporation, a company he joined in 2010. Prior to Volcano, Mr. Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law firms of Fulbright & Jaworski LLP and Matthews and Branscomb, P.C. Mr. Lippoldt received a B.B.A. in Finance, an M.A. in International Relations, and a J.D. from St Mary's University.

Neurocrine also announced the grant of an inducement award to Mr. Lippoldt pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules in connection with his employment with Neurocrine. In connection with the employment agreement, Mr. Lippoldt was granted an inducement award consisting of a stock option to purchase 95,000 shares of Neurocrine common stock. The stock option will vest over a period of four years, with 25% vesting on the first anniversary of the grant date and the balance vesting each month over the remaining three years. This award is subject to the terms and conditions of Neurocrine's Inducement Plan. This award was effective on November 3, 2014, the first business day of the first calendar month following the commencement of his employment with Neurocrine, and has an exercise price of $18.15 per share, which was the closing price of Neurocrine's common stock on the NASDAQ Global Select Market on that date. The award was granted as an inducement material to Mr. Lippoldt's employment pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
2. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
3. Neurocrine Biosciences Reports Third Quarter 2013 Results
4. Neurocrine Biosciences Reports Second Quarter 2013 Results
5. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
6. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
7. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
8. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
9. Neurocrine Biosciences Reports Third Quarter 2012 Results
10. Neurocrine Biosciences Reports Second Quarter 2012 Results
11. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... thermal denaturation in a cellular milieu; however, the broad application of this cellular ... simple platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, ... funding to three startups through the UConn Innovation Fund. The $1.5 million UConn ... affiliated with UConn. , The UConn Innovation Fund provides investments of up to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant from ... , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, ...
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences , ... sciences and healthcare industries, is pleased to announce Holger Braemer as Vice ... “USDM Europe GmbH” based in Germany. , Braemer is an integral part of ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):